Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics has suggested aficamten has a competitive clinical profile to BMS' drug – pointing to strong data on exercise capacity, symptoms, biomarkers, cardiac structure and function ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...

Royalty Pharma said its decision follows feedback from investors that the current structure made it difficult to ... capital for 14 experimental treatments, including Cytokinetics' heart disease drug ...

“With regulatory filings for aficamten already under review in This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics ...

The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ...